Spots Global Cancer Trial Database for A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
Official Title: A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma
Study ID: NCT00000994
Conditions
Interventions
Study Description
Brief Summary: To determine whether taking zidovudine (AZT) will change the natural course of HIV infection in patients with AIDS-associated Kaposi's sarcoma (KS) and whether administering AZT at a similar dose but at different intervals will reduce toxicity in a more manageable treatment plan. Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent. AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether AZT therapy will delay the development of opportunistic infections and/or KS lesions.
Detailed Description: Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent. AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether AZT therapy will delay the development of opportunistic infections and/or KS lesions. Patients are divided into two treatment groups, the first receiving AZT for 5 doses a day, and the second receiving AZT for 3 doses per day. A placebo group is divided into two to match the two treatment groups. Study patients are stratified according to whether they have (a) 10 or fewer cutaneous lesions without oral lesions or (b) more extensive cutaneous lesions or oral lesions. Patients are seen on an outpatient basis weekly for the first 2 months, every other week for the next 2 months, and monthly thereafter.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
UCLA CARE Ctr, Los Angeles, California, United States
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States
Stanford Univ School of Medicine, Stanford, California, United States
Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States
Louisiana State Univ Med Ctr / Tulane Med School, New Orleans, Louisiana, United States
Tulane Univ School of Medicine, New Orleans, Louisiana, United States
Johns Hopkins Hosp, Baltimore, Maryland, United States
Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
Univ of Minnesota, Minneapolis, Minnesota, United States
Bronx Veterans Administration / Mount Sinai Hosp, Bronx, New York, United States
SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States
City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst, New York, United States
Beth Israel Med Ctr / Peter Krueger Clinic, New York, New York, United States
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
Mount Sinai Med Ctr, New York, New York, United States
Univ of Rochester Medical Center, Rochester, New York, United States
SUNY / State Univ of New York, Syracuse, New York, United States
Duke Univ Med Ctr, Durham, North Carolina, United States
Contact Details
Name: Valentine FT
Affiliation:
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
